<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04112823</url>
  </required_header>
  <id_info>
    <org_study_id>2019-10562</org_study_id>
    <nct_id>NCT04112823</nct_id>
  </id_info>
  <brief_title>Dexamethasone for Migraine - Dose Comparison</brief_title>
  <official_title>Dexamethasone for Acute Migraine. A Randomized Dose-comparison Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Montefiore Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Montefiore Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dexamethasone is an evidence-based treatment of acute migraine. This is a randomized
      comparison of two different doses of dexamethasone for acute migraine.

      All patients will also be treated with metoclopramide.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2019</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with headaches who have sustained headache relief for 48 hours</measure>
    <time_frame>48 hours</time_frame>
    <description>The primary outcome for this study will be sustained headache relief for 48 hours: achieving a headache intensity = &quot;none&quot; or &quot;mild&quot; within two hours of medication administration and maintaining this level, without requiring additional headache medication, for the entire 48 follow-up period</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with headache who have relief within two hours of medication administration</measure>
    <time_frame>Two hours</time_frame>
    <description>achieving a headache level = mild or none within two hours of medication administration without requiring rescue medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days with headache</measure>
    <time_frame>One week</time_frame>
    <description>Number of headache days during the week after ED discharge</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>Dexamethasone 4mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dexamethasone 4mg, administered intravenously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexamethasone 16mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dexamethasone 16mg, administered intravenously</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone 4mg</intervention_name>
    <description>Dexamethasone 4mg + metoclopramide 10mg, intravenously</description>
    <arm_group_label>Dexamethasone 4mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone 16mg</intervention_name>
    <description>Dexamethasone 16mg + metoclopramide 10mg, intravenously</description>
    <arm_group_label>Dexamethasone 16mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Moderate or severe migraine

        Exclusion Criteria:

          -  Medication contra-indication

          -  Concern for secondary cause of headache
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benjamin Friedman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montefiore Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eddie Irizarry, MD</last_name>
    <phone>718-920-6626</phone>
    <email>eddiriza@montefiore.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marleny Castillo</last_name>
    <phone>718-920-6626</phone>
    <email>marcasti@montefiore.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benjamin Friedman, MD</last_name>
      <phone>718-920-6626</phone>
      <email>befriedm@montefiore.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>September 30, 2019</study_first_submitted>
  <study_first_submitted_qc>October 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 2, 2019</study_first_posted>
  <last_update_submitted>December 19, 2019</last_update_submitted>
  <last_update_submitted_qc>December 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Montefiore Medical Center</investigator_affiliation>
    <investigator_full_name>Benjamin W. Friedman, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

